GlassScriptPhysician profile
Elwin G Bustos
NPI 1467543686
$8,899.17
in general payments reported to CMS, 2019-2025
42 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $994 · 2021: $1,727 · 2022: $1,480 · 2023: $1,096 · 2024: $1,498 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,671.98 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,846.03 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $1,778.64 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $726.10 | 2020-2024 | Acthar |
| Novo Nordisk INC | $543.85 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $430.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $344.38 | 2021-2025 | Otezla, Repatha, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $249.64 | 2021-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $211.38 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $192.50 | 2020-2024 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $187.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.06 | 2020-2025 | Jardiance |
| Pfizer INC. | $149.94 | 2020-2022 | |
| Impulse Dynamics (USA) INC. | $146.78 | 2022 | |
| Ardelyx, INC. | $144.90 | 2024 | Xphozah 30 Mg, Ibsrela |
| Kowa Pharmaceuticals America, INC. | $137.34 | 2025 | Zoryve |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elwin Bustos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.